Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
- Conditions
- Central Line Associated Blood Stream Infections (CLABSI)
- Interventions
- Drug: (taurolidine and heparin) catheter lock solution
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- CorMedix
- Target Recruit Count
- 200
- Registration Number
- NCT06822426
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Rhode Island Hospital, Providence, Rhode Island, United States
🇺🇸Emory University Hospital - GCRC, Atlanta, Georgia, United States
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
- Conditions
- Catheter-Related Infections
- Interventions
- Drug: (taurolidine and heparin) catheter lock solutionDrug: Standard of Care
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- CorMedix
- Target Recruit Count
- 36
- Registration Number
- NCT06714864
- Locations
- 🇺🇸
Children's of Alabama/University of Alabama, Birmingham, Alabama, United States
🇺🇸Stanford, Palo Alto, California, United States
🇺🇸Nemours Children's Hospital - DE, Wilmington, Delaware, United States
Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
- Conditions
- Catheter-related Bloodstream Infection
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- CorMedix
- Registration Number
- NCT06707480
Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
- Conditions
- Kidney Failure, ChronicCatheter-Related Infections
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- CorMedix
- Target Recruit Count
- 806
- Registration Number
- NCT02651428
- Locations
- 🇺🇸
Riverside Nephrology Physicians/Van Buren Dialysis center, Riverside, California, United States
🇺🇸North America Research Institute, San Dimas, California, United States
🇺🇸North Beach Dialysis Center Inc., Miami Gardens, Florida, United States
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- CorMedix
- Registration Number
- NCT01391520
- Prev
- 1
- 2
- Next
News
CorMedix Acquires Melinta Therapeutics for $300 Million to Expand Anti-Infective Portfolio
CorMedix has entered a definitive agreement to acquire Melinta Therapeutics for $300 million, adding seven marketed infectious disease products to its portfolio.
CorMedix Announces Positive Preliminary Q4 2024 Results and Business Updates
CorMedix reported preliminary unaudited net revenue of approximately $31 million for Q4 2024 and $43 million for FY 2024, exceeding previous guidance.